Sequoia China Seed Fund Leads Pre-A Round in Asia Regenerative Medicine to Advance Bioartificial Organ Development

VCBeat (WeChat: vcbeat) has learned that Huayuan Regenerative Medicine recently completed a Pre-A financing round of tens of millions of yuan, led by HongShan China Seed Fund, with additional investment from existing shareholders.

AR Regenerative Medicine, established in 2018, is a research and development company dedicated to manufacturing bio-artificial organs capable of replacing donor organs, leveraging human stem cell technology and tissue engineering. The company is committed to addressing the shortage of organ donors and extending human life with high quality. AR has established five cell and material laboratories in Shenzhen, Guangzhou, Wuhan, and Hong Kong. Its technical and business team, comprising experts in cells, biomaterials, and clinical practice, numbers 70 professionals, making it one of the larger R&D teams for bio-artificial organs in Asia.

Regarding this round of financing, Zheng Lixin, CEO of AR (Huayuan Regenerative Medicine), who has previously held positions at McKinsey & Company, Johnson & Johnson, Sino-American SmithKline, and Glaxo Wellcome in the UK, stated: “Throughout the evolution of clinical therapeutic technologies—from early natural remedies and chemical drugs to traditional medical devices and, more recently, antibody-based biologics—medical advancements have gradually increased the average human lifespan to approximately 80 years. However, the inevitable process of aging, along with unexpected diseases and accidents, has led to a significant incidence of organ failure. In end-stage organ diseases such as diabetes and kidney disease, patients often suffer immensely, experiencing a sharp decline in quality of life. Although organ transplantation remains the optimal treatment, its potential is constrained by a severe shortage of donor organs. The mission of AR is to leverage increasingly mature stem cell and tissue engineering technologies to manufacture human-derived bioengineered organs suitable for transplantation, thereby treating end-stage organ diseases and addressing the need for transplants.”

HongShan is one of the earliest investment firms in China to make deep inroads into the healthcare sector, maintaining a long-term forward-looking focus on regenerative medicine and continuously investing in innovative companies related to organs. The investment from HongShan’s Seed Fund will not only provide development capital for AR (Huayuan Regenerative Medicine) but, more importantly, bring international perspective, extensive industry resources, and strategic insights for corporate growth.

With the support of HongShan China’s Seed Fund, AR will continue to intensify its R&D efforts in organ regeneration and repair, and collaborate with industry peers to advance the technological innovation and clinical application of China’s organ transplantation industry, thereby benefiting society and patients.